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Patients with glycogen storage disease type Ia (GSD-Ia)
develop renal disease of unknown etiology despite intensive
dietary therapies. This renal disease shares many clinical and
pathological similarities to diabetic nephropathy. We studied
the expression of angiotensinogen, angiotensin type 1
receptor, transforming growth factor-b1, and connective
tissue growth factor in mice with GSD-Ia and found them
to be elevated compared to controls. While increased renal
expression of angiotensinogen was evident in 2-week-old
mice with GSD-Ia, the renal expression of transforming
growth factor-b and connective tissue growth factor did not
increase for another week; consistent with upregulation of
these factors by angiotensin II. The expression of fibronectin
and collagens I, III, and IV was also elevated in the kidneys
of mice with GSD-Ia, compared to controls. Renal fibrosis
was characterized by a marked increase in the synthesis
and deposition of extracellular matrix proteins in the renal
cortex and histological abnormalities including tubular
basement membrane thickening, tubular atrophy, tubular
dilation, and multifocal interstitial fibrosis. Our results
suggest that activation of the angiotensin system has an
important role in the pathophysiology of renal disease in
patients with GSD-Ia.
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Glycogen storage disease type Ia (GSD-Ia, MIM232200) is
an autosomal recessive disorder caused by a deficiency in
glucose-6-phosphatase-a (G6Pase-a, also known as G6PC),
a key enzyme in glucose homeostasis that catalyzes the hydro-
lysis of glucose-6-phosphate (G6P) to glucose and phosphate
in the terminal step of gluconeogenesis and glycogenolysis.1
GSD-Ia patients manifest a phenotype of disturbed glucose
homeostasis characterized by fasting hypoglycemia, hepato-
megaly, nephromegaly, hypercholesterolemia, hypertri-
glyceridemia, hyperuricemia, lactic acidemia, and growth
retardation.1 Although renal involvement in GSD-Ia was
noted in von Gierke’s pathological description,2 and kidney
enlargement is commonly seen in GSD-Ia, chronic renal
disease was not widely recognized as a major complication
until the late 1980s when it was reported by Chen et al.3 The
renal biopsies of GSD-Ia patients revealed interstitial fibrosis,
tubular atrophy, and focal segmental glomerulosclerosis with
marked glomerular basement membrane thickening, which
was subsequently confirmed in additional GSD-Ia patients.4,5
Renal disease as a long-term complication in GSD-Ia is now
well established. Over the last two and a half decades, effec-
tive dietary therapies, including nocturnal nasogastric infusion
of glucose6 and/or oral administration of uncooked corn-
starch7 have significantly alleviated the metabolic abnorm-
alities and delayed the clinical manifestation of chronic renal
disease and renal insufficiency in GSD-Ia patients. However,
glomerular hyperfiltration, hypercalciuria, hypocitraturia that
worsens with age, and urinary albumin excretion still occur in
metabolically compensated GSD-Ia patients.8,9 While the
molecular basis of the GSD-Ia disorder is now known, the
molecular mechanism(s) responsible for the development of
renal disease in GSD-Ia is still poorly understood.
Renal disease in GSD-Ia5,10 exhibits a similar clinical
course and pathology to diabetic nephropathy.11,12 Both dys-
functions start with a long period of silent disease during
which glomerular hyperfiltration is the only demonstrable
renal abnormality. This is followed by the development of
microalbuminuria, proteinuria, and, ultimately, renal failure.
Pathologically, both exhibit interstitial fibrosis, tubular
atrophy, and glomerulosclerosis with marked glomerular
basement membrane thickening. Tissue fibrosis observed in
many kidney diseases including diabetic nephropathy is the
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result of excessive accumulation of extracellular matrix
(ECM) proteins,13,14 including fibronectin and collagens
type I, III, and IV. The ECM proteins accumulate during the
evolution of tubulointerstitial fibrosis and glomerulosclero-
sis, contributing to the impairment of renal function and
the eventual organ failure.13–15 Studies have shown that the
angiotensin (Ang) system plays a pivotal role in many of the
associated pathophysiologic changes in renal fibrosis.15–19
In the Ang system, angiotensinogen (Agt) is the precursor
of the multifunctional cytokine, Ang II, which is produced
from two sequential enzymatic reactions—the conversion
of Agt to Ang I by renin and the conversion of Ang I to Ang II
by the Ang converting enzyme.20 Ang II stimulates the proli-
feration of mesangial cells, glomerular endothelial cells,
and fibroblasts, and acts as a profibrogenic factor.15–19 Many
profibrotic effects of Ang II are mediated by the multi-
functional growth factor, transforming growth factor-b1
(TGF-b1),15 whose expression is also augmented by Ang II.21
TGF-b1 acts to increase the expression of the ECM genes
and also inhibits the production of ECM degradative
proteins,15,22,23 leading to the ECM protein deposition that
typifies progressive renal disease. In addition, TGF-b1 is a
potent inducer of the epithelial-to-mesenchymal transition
that characterizes the phenotype of renal interstitial fibro-
sis.15 The TGF-b1 induced renal disease is characterized by
accumulation of matrix protein, interstitial fibrosis, mesan-
gial expansion, and glumerulosclerosis.15,22–24 Ang II also
induces the expression of connective tissue growth factor
(CTGF),25 a prosclerotic cytokine and a TGF-b1-inducible
immediate early gene that acts downstream of TGF-b1.26,27
CTGF mediates TGF-b1-stimulated matrix protein expres-
sion and plays a key role in progressive renal fibrosis.
All components of the Ang system are found in the renal
proximal tubular cells,20 where G6Pase-a is primarily
expressed.28 GSD-Ia patients suffer from hyperuricemia
despite intensive dietary therapies.1 Studies of an experi-
mentally induced mild hyperuricemia in rats have suggested
that an elevation in circulating serum uric acid is strongly
associated with the development of renal disease.29,30 These
studies also showed that a uric acid-induced activation of the
intrarenal Ang system plays a key role in hyperuricemia-
mediated renal damage.29,30 The kidneys of GSD-Ia patients
also have increased levels of G6P, the intracellular form of
glucose, resulting from enhanced glycogenolysis and gluco-
neogenesis, compounded by the inability of these patients to
hydrolyze G6P to glucose.1 High glucose stimulated mRNA
expression and protein synthesis of Agt in proximal tubular
epithelial cells.31 We hypothesized that the Ang system may
be implicated in GSD-Ia nephropathy.
In previous studies of the biology and pathophysiology of
GSD-Ia, we generated a G6Pase-a-deficient mouse strain that
faithfully mimics the human disorder with the metabolic
abnormalities characteristic of a disturbed glucose home-
ostasis with the exception of lactic acidemia.32 In this study,
we show that the renal Ang system-mediated profibrotic
pathway is upregulated in GSD-Ia mice, providing one
mechanism that can lead to the development of renal disease.
RESULTS
Increased renal expression of Agt, Ang peptides, and AT1
in GSD-Ia mice
Quantitative real-time RT-PCR (reverse transcription-PCR)
analysis showed that renal Agt mRNA levels were similar
between 1-week-old GSD-Ia and their wild-type littermates
(Figure 1a). While renal Agt transcripts increased only
slightly in wild-type mice during postnatal development,
postnatal renal Agt mRNA increased markedly in the GSD-Ia
mice (Figure 1a). Consequently, renal Agt mRNA in 2-, 3-, 4-,
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Figure 1 | Analysis of renal expression of the Ang system in GSD-Ia mice. (a) Quantification of Agt mRNA in wild-type (J) and GSD-Ia
(K) mice during postnatal development using real-time RT-PCR. Results are the mean±s.e.m. Each point represents the average of 5 or more
animals. **Po0.01; ***Po0.001. (b) Western blot analysis of Agt in the kidneys of 6-week-old wild-type (þ /þ ) and GSD-Ia (/) mice.
(c) Immunohistochemical analysis of Agt, Ang I, and Ang II in the kidneys of GSD-Ia mice. Plates shown are kidneys from 6-week-old wild-type
(þ /þ ) and GSD-Ia (/) mice at magnifications of  50 (left panels) and  200 (right panels). Representative experiments are shown.
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and 6-week-old GSD-Ia mice showed on average a 4-fold
higher level, compared to the age-matched wild-type mice.
Western blot analysis confirmed that the increased RNA
expression correlated with an increased expression of Agt
proteins in the kidneys of GSD-Ia mice (Figure 1b).
Immunohistochemical analysis using a polycloncal antibody
against Ang I/II (N-10) that detects Agt, Ang I, and Ang II
showed that within the kidneys of wild-type mice, low levels
of these peptides were expressed in cortical tubular epithelial
cells (Figure 1c). In contrast, GSD-Ia kidneys expressed signi-
ficantly high levels of Agt, Ang I, and Ang II in numerous
proximal tubular epithelial cells (Figure 1c).
Angiotensin II acts through two specific receptors,33,34
Ang type 1 (AT1) and Ang type 2 (AT2). Real-time RT-PCR
analysis showed that renal AT1 mRNA levels in 1-week-old
GSD-Ia mice were only 65% of wild-type expression (Figure 2a).
However, while AT1 mRNA in wild-type mice increased
slowly during postnatal development, the levels increased rapidly
in GSD-Ia mice. As a consequence, the renal AT1 mRNA in
4- and 6-week-old GSD-Ia mice averaged 1.2- and 1.3-fold
higher, respectively, than the wild-type mice (Figure 2a).
Western blot analysis again confirmed that this correlated
with an increase in the AT1 protein expression (Figure 2b). In
contrast, renal expression of AT2 was similar between GSD-Ia
and wild-type mice (data not shown).
Increased renal expression of TGF-b1 and CTGF in GSD-Ia
mice
The expression of TGF-b1 can be induced by Ang II,21 while
the expression of CTGF can be induced by Ang II25 and
TGF-b1,26,27 both playing key roles in Ang II-mediated renal
fibrosis.15–19.Real-time RT-PCR was used to measure the level
of expression of TGF-b1 and CTGF in the kidneys of GSD-Ia
and wild-type mice. At 2 weeks of age, the levels of TGF-b1
mRNA remained similar between the GSD-Ia and wild-type
mice (Figure 3a). However, in mice 3 weeks or older, renal
TGF-b1 transcripts increased more rapidly in the GSD-Ia
mice than their wild-type littermates (Figure 3a). As a result,
renal TGF-b1 mRNA in 3-, 4-, and 6-week-old GSD-Ia mice
averaged 1.6- to 1.9-fold higher compared to wild-type mice.
Again, protein expression correlated with the RNA expression
profiles. A quantitative immunoassay confirmed the increase
in renal expression of the TGF-b1 protein in the kidneys
of GSD-Ia mice compared to the controls (Figure 3b).
Immunohistochemical analysis showed that in wild-type
kidneys, very low levels of TGF-b1 were detected in randomly
scattered cortical tubular epithelial cells (Figure 3c). In GSD-
Ia kidneys, moderately high levels of TGF-b1 were expressed
in the glomeruli and proximal tubular epithelial cells. In
addition, there were occasional low levels of TGF-b1 found in
distal convoluted tubular epithelial cells and collecting
tubular epithelial cells.
Real-time RT-PCR analysis showed that the activation
profile of CTGF mRNA in GSD-Ia mice was similar to that of
the TGF-b1 transcripts (Figure 4a) with CTGF mRNA in
3-, 4-, and 6-week-old GSD-Ia kidneys averaging 1.7-, 2.5-,
and 3.0-fold higher, respectively, than the levels observed in
wild-type kidneys. Western blot analysis confirmed that the
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Figure 2 | Analysis of renal expression of AT1 in GSD-Ia mice.
(a) Quantification of AT1 mRNA in wild-type (J) and GSD-Ia (K) mice
during postnatal development using real-time RT-PCR. Results are
the mean±s.e.m. Each point represents the average of five or more
animals. *Po0.05. (b) Western blot analysis of AT1 in the kidneys
of 6-week-old wild-type (þ /þ ) and GSD-Ia (/) mice.
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Figure 3 | Analysis of renal expression of TGF-b1 in GSD-Ia mice.
(a) Quantification of TGF-b1 mRNA in wild-type (J) and GSD-Ia
(K) mice during postnatal development using real-time RT-PCR.
Results are the mean±s.e.m. Each point represents the average
of five or more animals. *Po0.05; **Po0.01. (b) Quantification of
TGF-b1 protein levels in the kidneys of 6-week-old wild-type (þ /þ ;
n¼ 14) and GSD-Ia (/; n¼ 14) mice by immunoassays. *Po0.05.
(c) Immunohistochemical analysis of TGF-b1 in the kidney of
GSD-Ia mice. Plates shown are kidneys from 6-week-old wild-type
(þ /þ ) and GSD-Ia (/) mice at magnifications of  50 (left panels)
and  200 (right panels). Representative experiments are shown.
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increased RNA expression correlated with an increased
expression of CTGF proteins in the kidneys of GSD-Ia mice
(Figure 4b). Immunohistochemical analysis showed that in
wild-type kidneys, very low levels of CTGF immunostaining
were detected in cortical tubular epithelial cells with low
levels at the corticomedullary junctions (Figure 4c). In GSD-
Ia kidneys, significant high levels of CTGF protein were
detected in corticomedullary tubules (Figure 4c). No increase
in glomerular CTGF expression was observed.
Increased production of renal ECM proteins in GSD-Ia mice
While renal fibronectin mRNA levels in GSD-Ia mice were
slightly lower than those in wild-type mice during the first 2
weeks of postnatal development, renal fibronectin transcripts
in GSD-Ia mice increased markedly thereafter (Figure 5a).
Consequently, renal fibronectin mRNA in 3- and 6-week-old
GSD-Ia mice was, on average, 2.6-fold higher than in wild-
type littermates.
During the first 2 weeks of postnatal development, renal
levels of mRNA for collagens a1(I), a2(I), a1(III), and a2(IV)
were similar between GSD-Ia and wild-type mice (Figure 5a).
As observed with fibronectin, renal collagen a1(I), a2(I),
a1(III), and a2(IV) transcripts increased more rapidly in
3- to 6-week-old GSD-Ia mice than in wild-type mice
(Figure 5a), with collagen a1(I), a2(I), a1(III), and a2(IV)
mRNA in the kidneys averaging a 1.7- to 2.6-fold increase
compared to wild-type littermates.
To further evaluate the profibrotic phenotype of GSD-Ia
kidneys, we investigated the production of the ECM proteins
in 6-week-old GSD-Ia and wild-type mice using immuno-
histochemical analysis. Within the kidneys of wild-type mice,
fibronectin was detected primarily in the glomerulus with
little in the renal tubules (Figure 5b). In contrast, the kidneys
of GSD-Ia mice expressed very high levels of fibronectin not
only in the glomeruli but also in the renal interstitium,
tubular epithelial cells, and tubular basement membranes
(Figure 5b). Similarly, synthesis of collagens a1(I) (data not
shown), a1(III) (data not shown), and a2(IV) (Figure 5c)
were also markedly increased in the kidneys of GSD-Ia mice,
primarily localized at the tubular basement membranes,
compared to the wild-type mice. These results confirmed the
appearance and development of interstitial fibrosis in the
kidneys of GSD-Ia mice.
The GSD-Ia mice manifest metabolic and histological
abnormalities
Nephromegaly is manifested clinically in GSD-Ia in both
humans and mice as a result of excessive glycogen deposition.1,32
The glycogen storage in the kidneys of wild-type mice is
low, with an average relative kidney weight of 1.2–1.4% of body
weight during the 6 weeks of postnatal development (Figure 6a).
On the other hand, kidney enlargement was already notable in
3-day-old GSD-Ia mice (Figure 6a). The severity of kidney
enlargement increased with age and the average kidney weight
of 6-week-old GSD-Ia mice was elevated more than 3-fold
relative to wild-type mice to 4.3% of body weight (Figure 6a).
An increase in serum levels of uric acid was also observed in
1-week-old GSD-Ia mice compared to the controls (Figure 6b)
peaking at age 2 weeks before leveling off at 6 weeks at a level
1.4-fold higher than the wild-type littermates (Figure 6b).
Serum creatinine, an index of altered renal function,35 was also
examined. The creatinine levels in the serum of 6-week-old
wild-type mice were 0.04±0.05 mg per 100 ml (Figure 6c). In
contrast, serum creatinine levels in 6-week-old GSD-Ia mice
were increased 10-fold, reaching 0.41±0.07 mg per 100 ml
(Figure 6c).
Histological examination showed that the architecture of
the kidneys in 6-week-old GSD-Ia mice was altered compared
to their wild-type littermates. Marked glycogen accumulation
in the cortex tubules resulted in enlargement of tubular
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Figure 4 | Analysis of renal expression of CTGF in GSD-Ia mice. (a) Quantification of CTGF mRNA in wild-type (K) and GSD-Ia (J)
mice during postnatal development using real-time RT-PCR. Results are the mean±s.e.m. Each point represents the average of five or more
animals. *Po0.05; **Po0.01. (b) Western blot analysis of CTGF in the kidneys of 6-week-old wild-type (þ /þ ) and GSD-Ia (/) mice.
(c) Immunohistochemical analysis of CTGF in the kidney of GSD-Ia mice. Plates shown are kidneys from 6-week-old wild-type (þ /þ ) and
GSD-Ia (/) mice at magnifications of  50 (left panels) and  200 (right panels). Representative experiments are shown.
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epithelial cells (Figure 7a). Renal pathology also included
tubular basement membrane thickening, tubular atrophy,
tubular dilation, multifocal mild interstitial fibrosis, and
increased Bowman’s capsule spaces (Figure 7a). Masson’s
trichrome staining further demonstrated multifocal areas of
mild-to-moderate interstitial fibrosis in GSD-Ia kidneys,
primarily in the corticomedullary region (Figure 7b).
DISCUSSION
Glycogen storage disease type Ia patients under good
metabolic control for hypoglycemia still experience longer-
term complications from the disease. They continue to suffer
from hyperlipidemia, hyperuricemia, hypercalciuria, hypoci-
traturia, and lactic acidemia and consequently, chronic renal
disease, of unknown etiology, remains a common complica-
tion of GSD-Ia.1,8,9 For those GSD-Ia patients who develop
renal insufficiency, the pathology includes interstitial fibrosis,
tubular atrophy, and focal segmental glomerulosclerosis.3–5
Recently, an increased expression of TGF-b1 was reported in a
renal biopsy of a GSD-Ia patient manifesting proteinuria,
interstitial fibrosis, and tubular atrophy,36 suggesting one
potential mechanism may be mediated by TGF-b1, but there
was no follow-up to the observation. In this study, we
examined the role of the Ang system in the development of
renal disease in GSD-Ia and showed that components of this
system are indeed upregulated in GSD-Ia mice relative to their
wild-type littermates. In particular, the expression of Agt, the
precursor of Ang I and Ang II,20 Ang I/Ang II, and the AT1
receptor, which mediates almost exclusively the Ang II-
mediated renal diseases,15–19 are elevated in the kidneys of
GSD-Ia mice. In addition, renal expression of the cytokines
that mediate most of the profibrogenic effects of Ang II,
namely TGF-b115,22,23 and CTGF,26,27 is also increased in GSD-
Ia mice. While the increase in renal Agt expression was evident
in 2-week-old GSD-Ia mice, the increase in renal expression of
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Figure 5 | Analysis of renal expression of fibronectin and collagens in GSD-Ia mice. (a) Quantification of mRNA for fibronectin, collagens
a1(I), a2(I), a1(III), and a2(IV) in wild-type (J) and GSD-Ia (K) mice during postnatal development using real-time RT-PCR. Results are the
mean±s.e.m. Each point represents the average of five or more animals. *Po0.05; **Po0.01; ***Po0.001. (b and c) Immunohistochemical
analysis of fibronectin (b) and collagen a2(IV) (c) deposition in the kidney of GSD-Ia mice. Plates shown are kidneys from 6-week-old wild-type
(þ /þ ) and GSD-Ia (/) mice at magnifications of  50 (left panels) and  200 (right panels). Representative experiments are shown.
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wild-type (J) and GSD-Ia (K) mice during postnatal development.
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TGF-b1 and CTGF was not observed until the GSD-Ia mice
were at least another week older. This is consistent with the
proposed mechanism because Ang II upregulates the expres-
sion of TGF-b121 and CTGF25 and should increase first. Also
as predicted by an Ang-mediated system, renal expression of
genes for ECM proteins, fibronectin, and collagens I, III, and
IV, was elevated in GSD-Ia mice, compared to the controls.
Renal fibrosis in GSD-Ia was further demonstrated by the
marked increase in the synthesis and deposition of these ECM
proteins in the renal cortex. Consistent with this, histological
examination in the kidneys of 6-week-old GSD-Ia mice
revealed tubular basement membrane thickening, tubular
atrophy, tubular dilation, increased Bowman’s capsule spaces,
and multifocal mild-to-moderate interstitial fibrosis. Taken
together, our results are consistent with Ang/TGF-b1/CTGF-
mediated renal fibrosis being at least one mechanism under-
lying the nephropathy occurring in GSD-Ia.
The actions of cytokines and growth factors including
Ang II, TGF-b1, and CTGF, which are upregulated by
glucose,31,37,38 also play important roles in diabetic nephro-
pathy,11,12,39,40 suggesting a common pathway that might
lead to renal disease in GSD-Ia and diabetes. While diabetes
is caused by a disturbance in insulin function, characterized
by uncontrolled hyperglycemia,41,42 GSD-Ia is characterized
by fasting hypoglycemia, caused by a deficiency in G6Pase-a.1
However, it is reasonable to suggest that there are some
common pathways that might be important in diabetes
and GSD-Ia. First, renal dysfunctions in both GSD-Ia and
diabetic nephropathy exhibit a similar clinical course and
pathology.5,10 Second, a common denominator for both
diabetes and GSD-Ia is the increase in the intracellular renal
levels of G6P—the intracellular form of glucose. Interestingly,
the glucose-stimulated expression of Ang and TGF-b1
was mediated by the G6P metabolite diacylglycerol,43 an
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Figure 7 | Histological analysis of the kidneys in GSD-Ia mice. (a) Plates show H&E stained kidney sections in 6-week-old wild-type (þ /þ )
and GSD-Ia (/) mice at magnifications of  50 (a and c) and  200 (b, d–f). Representative experiments are shown. (b) Masson’s trichrome
staining of kidney sections in 6-week-old wild-type (þ /þ ) and GSD-Ia (/) mice at magnifications of  50 (a and c) and  200 (b, d–f).
Interstatitial fibrosis is shown by the blue colored staining of the collagen fibers. The dilated tubules are denoted by asterisks.
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activator of the protein kinase C transduction pathway.31,37,43
In diabetic patients, hyperglycemia leads to an increase in the
renal uptake of glucose by a facilitated glucose transporter.44
The glucose is then converted efficiently to G6P by the low
Km hexokinase expressed in the kidney. In GSD-Ia patients,
the cause of increased G6P is different, stemming from
enhanced glycogenolysis and gluconeogenesis between meals.
However, the net outcome is the same, the elevation of
intracellular G6P. This may lead to some common con-
sequences. Where they differ is that in the case of GSD-Ia, the
increased G6P levels are maintained and compounded by the
inability of the patients to hydrolyze G6P back to glucose
when needed.1 As a result, the high intracellular G6P levels
drive excessive glycogen accumulation in the kidney and
trigger additional clinical manifestation of nephromegaly
seen in GSD-Ia,1 which can be observed as early as 3 days of
age. This is not the case in diabetic nephropathy and clearly
highlights the differences that also exist. For example,
hyperglycemia associated with diabetes increases the activity
of the polyol pathway, alters the redox state of pyridine
nucleotides, and induces glycation of proteins, all can lead to
renal damages.11 Nevertheless, an understanding of the
molecular and pathological bases of diabetic nephropathy
may help to provide clues to pathways that may unravel the
etiology of kidney dysfunctions in GSD-Ia.
Glycogen storage disease type Ia patients also manifest
hyperuricemia and hyperlipidemia,1 which can be indepen-
dent risk factors for the development and progression of renal
disease. Rats with mild hyperuricemia develop interstitial
renal injuries, which may occur through activation of the
intrarenal Ang system.29,30 Furthermore, the hyperuricemic
rats developed glomerular hypertrophy, and upon prolonged
hyperuricemia develop albuminuria and glomerulosclerosis.45
We have shown that serum levels of uric acid were elevated in
1-week-old GSD-Ia mice, which may also activate the Ang
system in GSD-Ia kidneys. Ang II acts through two seven-
transmembrane domain, G-protein-coupled receptors, AT1
and AT2.
33,34 In our study, we showed that renal expression of
the AT1 receptor, which is implicated almost exclusively with
the Ang II-mediated renal diseases,15–19 was elevated in GSD-
Ia mice. Mechanistically, this is quite reasonable. The
expression of the AT1 receptor can be induced by hyperch-
olesteremia and high levels of low density lipoproteins,46 both
clinical manifestations of GSD-Ia.1,47 Moreover, studies have
shown that overexpression of the AT1 receptor in podocytes of
transgenic rats results in structural podocyte damage leading
to focal segmental glomerulosclerosis.48
In conclusion, we have shown that renal disease in GSD-Ia
is mediated, at least in part, by the Ang/TGF-b1/CTGF
pathway, resulting in renal fibrosis characterized by increased
synthesis and deposition of ECM proteins.
MATERIALS AND METHODS
G6Pase-a-deficient GSD-Ia mice
All animal studies were conducted under an animal protocol
approved by the NICHD Animal Care and Use Committee. A
glucose therapy that consists of intraperitoneal injection of 25–100ml
of 15% glucose, every 12 h, was initiated on the first postnatal
day for GSD-Ia mice, as described previously.32 Mice that survived
weaning were given unrestricted access to Mouse Chow (Zeigler
Bros. Inc., Gardners, PA, USA). GSD-Ia is an autosomal recessive
disorder.1 Since the phenotypes of wild-type and heterozygous mice
are identical, with both exhibiting normal development and
metabolic functions,32 we use the designation ‘wild-type’ to refer
to both wild-type and heterozygous mice.
Quantitative real-time RT-PCR, western blot, serum, and
phenotype analyses
Total RNAs were isolated from the kidneys using the TRIzol Reagent
(Invitrogen Life Technologies, Carlsbad, CA, USA). The mRNA
expression was quantified by real-time RT-PCR, performed in triplicates,
in an Applied Biosystems (Foster City, CA, USA) 7300 Real-Time PCR
System using the gene-specific TaqMan Gene Expression Assays and
then normalized to GADPH RNA. The TaqMan Gene Expression Assays
used were Agt, Mm00599662_m1; AT1, Mm00558224_s1; TGF-b1,
Mm00441724_m1; CTGF, Mm00515790_g1; fibronectin, Mm01256734_
m1; procollagen a1(I), Mm00801666_g1; procollagen a2(I),
Mm00483888_m1; procollagen a1(III), Mm00802331_m1; procollagen
a2(IV), Mm00802386_m1; and GADPH, Mm99999915_g1. Data were
analyzed using the SDS v1.3 software (Applied Biosystems), and
expression levels normalized against the level of the appropriate
transcript in a wild-type mouse, which was arbitrarily defined as 1.
For western blot analysis, kidney lysates were resolved by electro-
phoresis through a 10% polyacrylamide-SDS gel and transblotted
onto polyvinylidene fluoride membranes (Millipore Co., Bedford,
MA, USA). The membranes were incubated with a goat polyclonal
antibody against Ang I/II (N-10), a rabbit polyclonal antibody
against AT1 (N-10), a mouse monoclonal antibody against b-actin;
all from Santa Cruz Biotechnology (Santa Cruz, CA, USA), or a
rabbit polyclonal antibody against CTGF (Abcam Inc., Cambridge,
MA, USA). The membranes were then incubated with the
appropriate horseradish peroxidase-conjugated secondary antibody
and the immunocomplex visualized using the ImmobilonTM western
chemiluminescent HRP substrate (Millipore). TGF-b1 was quanti-
fied using the Quantikine Mouse/Rat/Porcine/Canine TGF-b1
Immunoassay kit obtained from R&D Systems Inc.(Minneapolis,
MN, USA).
Blood samples were collected from the tail vein, serum uric acid
levels were analyzed using a kit obtained from Thermo Electron
(Louisville, CO, USA), and serum creatinine levels were analyzed
using a kit obtained from Cayman Chemical (Ann Arbor, MI, USA).
For hematoxylin and eosin (H&E) and Masson’s trichrome staining,
tissues were preserved in 10% neutral buffered formalin, embedded
in paraffin, and sectioned at 4–6 mm thickness.
Immunohistochemical analysis
Mouse kidneys were snap frozen, embedded in O.C.T. (Sakura
Finetek, Terrance, CA, USA), and sectioned at 6 mm thickness. To
identify Agt/Ang I/Ang II, TGF-b1, CTGF, and ECM proteins by
immunohistochemical analysis, tissue sections were prepared by
quenching the endogenous tissue peroxidases with 0.3% hydrogen
peroxide in 70% methanol for 30 min. The endogenous avidin/
biotin was blocked using the Avidin/Biotin Blocking Kit obtained
from Vector Laboratories (Burlingame, CA, USA). The sections
were then stained with a goat polyclonal antibody to Ang I/II
(N-10) (Santa Cruz Biotechnology), a goat antibody to collagen
a2(I) (Santa Cruz Biotechnology), a mouse monoclonal antibody to
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TGF-b1, or one of the rabbit polyclonal antibodies to CTGF,
fibronectin, collagen a1(I), or collagen a2 (IV), all from Abcam Inc.
The stained sections were then incubated with biotinylated anti-goat
IgG, biotinylated anti-mouse IgG, or biotinylated anti-rabbit IgG
(Vector Laboratories), and the immune complexes were detected
using an ABC kit and DAB Substrate from Vector Laboratories
according to the manufacturer’s instructions. The sections were
finally counterstained with hematoxylin before mounting.
Statistical analysis
The unpaired t-test was performed using the GraphPad Prism
Program, version 4 (GraphPad Software, San Diego, CA, USA).
Values were considered statistically significant at Po0.05.
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